Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its immuno-oncology product candidates include FATE-NK100, a natural killer (NK) cell cancer immunotherapy that consists of adaptive memory NK cells; FT500 induced pluripotent stem cells (iPSC)-derived NK cell product candidate for the treatment of advanced solid tumors; FT516 engineered iPSC-derived NK cell product candidate for the treatment of hematologic/solid tumors; and FT819 engineered chimeric antigen receptor 19 iPSC-derived T-cell product candidate for hematologic/solid tumors. The company's immuno-regulation product candidates comprise ProTmune, an investigational programmed cellular immunotherapy for use as a next-generation allogeneic hematopoietic cell transplantation cell graft; ToleraCyte for the treatment of autoimmune and inflammatory diseases; and FT300 iPSC-derived myeloid derived suppressor cell product candidate for the treatment of autoimmune diseases. Fate Therapeutics, Inc. has a research collaboration and license agreement with Memorial Sloan Kettering Cancer Center to develop off-the-shelf engineered T-cell product candidates; a research collaboration partnership with the University of California San Diego to develop off-the-shelf chimeric antigen receptor-targeted natural killer cell cancer immunotherapies. It also has a strategic research collaboration and license agreement with Juno Therapeutics, Inc. to identify small molecule modulators that enhance the function of T cells; and a collaboration agreement with ONO Pharmaceutical Co., Ltd. for the development and commercialization of two off-the-shelf CAR-T cell product candidates. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:FATE
Previous Symbol
CUSIPN/A
Phone858-875-1800
Debt
Debt-to-Equity Ratio0.07
Current Ratio9.44
Quick Ratio9.44
Price-To-Earnings
Trailing P/E Ratio-12.45
Forward P/E Ratio-10.50
P/E GrowthN/A
Sales & Book Value
Annual Sales$4.11 million
Price / Sales199.37
Cash FlowN/A
Price / CashN/A
Book Value$2.70 per share
Price / Book4.70
Profitability
EPS (Most Recent Fiscal Year)($1.02)
Net Income$-42,950,000.00
Net Margins-1,536.05%
Return on Equity-68.57%
Return on Assets-50.27%
Miscellaneous
Employees80
Outstanding Shares64,520,000
Market Cap$820.68 million
OptionableOptionable
Fate Therapeutics (NASDAQ:FATE) Frequently Asked Questions
What is Fate Therapeutics' stock symbol?
Fate Therapeutics trades on the NASDAQ under the ticker symbol "FATE."
How were Fate Therapeutics' earnings last quarter?
Fate Therapeutics Inc (NASDAQ:FATE) posted its earnings results on Thursday, November, 1st. The biopharmaceutical company reported ($0.31) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.25) by $0.06. The biopharmaceutical company earned $1.03 million during the quarter, compared to analysts' expectations of $1.24 million. Fate Therapeutics had a negative return on equity of 68.57% and a negative net margin of 1,536.05%. The company's revenue for the quarter was up .0% on a year-over-year basis. During the same period in the prior year, the business posted ($0.26) earnings per share. View Fate Therapeutics' Earnings History.
When is Fate Therapeutics' next earnings date?
What price target have analysts set for FATE?
9 analysts have issued 1 year price targets for Fate Therapeutics' shares. Their predictions range from $12.00 to $23.00. On average, they expect Fate Therapeutics' share price to reach $18.5714 in the next year. This suggests a possible upside of 46.2% from the stock's current price. View Analyst Price Targets for Fate Therapeutics.
What is the consensus analysts' recommendation for Fate Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fate Therapeutics in the last year. There are currently 2 hold ratings and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fate Therapeutics.
What are Wall Street analysts saying about Fate Therapeutics stock?
Here are some recent quotes from research analysts about Fate Therapeutics stock:
- 1. According to Zacks Investment Research, "Fate Therapeutics, Inc. is a biopharmaceutical company. The company focused on the discovery and development of adult stem cell modulators to treat hematologic malignancies, lysosomal storage disorders and muscular dystrophies. Fate Therapeutics, Inc. is headquartered in San Diego, California. " (9/21/2018)
- 2. HC Wainwright analysts commented, "Our $12 price target is based on a sum-of-the-parts analysis based on probability-adjusted revenue forecasts for ProTmune and FATE-NK100. We use the net present value of our revenue forecast through 2026, apply a 40% probability of success for 2Q18 fully diluted net cash estimate of $0.84/share to arrive at our $12 price target. We value the early stage pipeline and Juno collaboration at $2.32/share. We assume a 25% discount rate for the NPV of the pipeline and a P/S multiple of 4x." (8/7/2018)
Has Fate Therapeutics been receiving favorable news coverage?
Media coverage about FATE stock has trended somewhat positive on Saturday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Fate Therapeutics earned a news sentiment score of 1.7 on InfoTrie's scale. They also gave media headlines about the biopharmaceutical company a news buzz of 8.0 out of 10, meaning that recent media coverage is very likely to have an effect on the company's share price in the near future.
Who are some of Fate Therapeutics' key competitors?
Some companies that are related to Fate Therapeutics include argenx (ARGX), Allogene Therapeutics (ALLO), Repligen (RGEN), China Biologic Products (CBPO), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Regenxbio (RGNX), Aerie Pharmaceuticals (AERI), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Spark Therapeutics (ONCE), Rubius Therapeutics (RUBY), Autolus Therapeutics (AUTL) and Orchard Therapeutics (ORTX).
Who are Fate Therapeutics' key executives?
Fate Therapeutics' management team includes the folowing people:
- Mr. J. Scott Wolchko, Founder, CEO, Pres, Principal Financial Officer, Principal Accounting Officer & Director (Age 48)
- Dr. Daniel D. Shoemaker, Chief Scientific Officer (Age 50)
- Dr. Chris M. Storgard, Consultant (Age 52)
- Ms. Cindy R. Tahl, Gen. Counsel & Corp. Sec. (Age 45)
- Mr. Jim Beitel M.B.A., Sr. VP of Corp. Devel.
Who are Fate Therapeutics' major shareholders?
Fate Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Redmile Group LLC (16.39%), FMR LLC (11.84%), Franklin Resources Inc. (8.30%), BlackRock Inc. (5.38%), Artal Group S.A. (3.39%) and Partner Fund Management L.P. (2.33%). Company insiders that own Fate Therapeutics stock include Chris Storgard, Cindy Tahl, Daniel D Shoemaker, Redmile Group, Llc and William H Rastetter. View Institutional Ownership Trends for Fate Therapeutics.
Which major investors are selling Fate Therapeutics stock?
FATE stock was sold by a variety of institutional investors in the last quarter, including Franklin Resources Inc., Virtus ETF Advisers LLC, Bank of New York Mellon Corp, Vident Investment Advisory LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Credit Suisse AG and TIAA CREF Investment Management LLC. View Insider Buying and Selling for Fate Therapeutics.
Which major investors are buying Fate Therapeutics stock?
FATE stock was bought by a variety of institutional investors in the last quarter, including Redmile Group LLC, Partner Fund Management L.P., FMR LLC, Artal Group S.A., Aquilo Capital Management LLC, Jennison Associates LLC, BlackRock Inc. and Monashee Investment Management LLC. Company insiders that have bought Fate Therapeutics stock in the last two years include Chris Storgard, Redmile Group, Llc and William H Rastetter. View Insider Buying and Selling for Fate Therapeutics.
How do I buy shares of Fate Therapeutics?
Shares of FATE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fate Therapeutics' stock price today?
One share of FATE stock can currently be purchased for approximately $12.70.
How big of a company is Fate Therapeutics?
Fate Therapeutics has a market capitalization of $820.68 million and generates $4.11 million in revenue each year. The biopharmaceutical company earns $-42,950,000.00 in net income (profit) each year or ($1.02) on an earnings per share basis. Fate Therapeutics employs 80 workers across the globe.
What is Fate Therapeutics' official website?
How can I contact Fate Therapeutics?
Fate Therapeutics' mailing address is 3535 GENERAL ATOMICS COURT SUITE 200, SAN DIEGO CA, 92121. The biopharmaceutical company can be reached via phone at 858-875-1800 or via email at [email protected]
MarketBeat Community Rating for Fate Therapeutics (NASDAQ FATE)
MarketBeat's community ratings are surveys of what our community members think about Fate Therapeutics and other stocks. Vote "Outperform" if you believe FATE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FATE will underperform the S&P 500 over the long term. You may vote once every thirty days.
